How to use the new 2017 Japanese guidelines for multiple sclerosis and neuromyelitis optica-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

How to use the new 2017 Japanese guidelines for multiple sclerosis and neuromyelitis optica

Published:2017-09-21 Issue:4 Volume:8 Page:351-360
ISSN:1759-1961
Container-title:Clinical and Experimental Neuroimmunology
language:en
Short-container-title:Clin Exp Neuroimmunol

Author:

Matsui Makoto¹

Affiliation:

1. Department of Neurology; Kanazawa Medical University; Uchinada, Ishikawa Japan

Funder

Health and Labor Sciences Research

Ministry of Health, Labour and Welfare

Publisher

Wiley

Subject

Neurology (clinical),Immunology and Microbiology (miscellaneous),Immunology,Neuroscience (miscellaneous)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cen3.12414/fullpdf

Reference7 articles.

1. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria;Polman;Ann Neurol,2011

2. Japanese guidelines for fingolimod in multiple sclerosis: putting into practice;Matsui;Clin Exp Neuroimmunol,2014

3. Japanese Society of Neurological Therapeutics web site https://www.jsnt.gr.jp/guideline/tahatsu.html

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Delayed visual improvement in a pediatric patient with anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder after acute immunomodulatory treatment: A case report;Brain and Development Case Reports;2024-06

2. Dynamic changes in patient admission and their disabilities in multiple sclerosis and neuromyelitis optica: A Japanese nationwide administrative data study;Multiple Sclerosis and Related Disorders;2024-01

3. Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in China;Therapeutic Advances in Neurological Disorders;2024-01

4. Systematic review and network meta‐analysis comparing ofatumumab with other disease‐modifying therapies available in Japan for the treatment of patients with relapsing multiple sclerosis;Clinical and Experimental Neuroimmunology;2022-07-12

5. Multiple sclerosis clinical practice guidelines provide few complementary and alternative medicine recommendations: A systematic review;Complementary Therapies in Medicine;2021-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3